Search

Displaying results 671 - 680 of 5383 in total
  1. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    USA. … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  2. Drug

    Trimetazidine

    go.drugbank.com/drugs/DB09069
    ApprovedInvestigational

    [A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … [A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems.

  3. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745]

  4. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. … Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.

  5. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma

  6. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.

    Categories: Antihistamines for Systemic Use
  7. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L48016] In patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g.

  9. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  10. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    A barbiturate with hypnotic and sedative properties (but not antianxiety). … Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)